Last updated on April 2019

Study to Investigate Efficacy Safety and Pharmacokinetics of BT595 in Subjects With PID

Brief description of study

This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)

Clinical Study Identifier: NCT02810444

Find a site near you

Start Over

Investigational site # 4901

Sankt Augustin, Germany
  Connect »